{"nctId":"NCT01345058","briefTitle":"Add on Lacosamide Versus High Dose Monotherapy","startDateStruct":{"date":"2011-08-01","type":"ACTUAL"},"conditions":["Epilepsy"],"count":56,"armGroups":[{"label":"Lacosamide + Low-Dose Levetiracetam","type":"EXPERIMENTAL","interventionNames":["Drug: lacosamide","Drug: levetiracetam"]},{"label":"Control Group (High-Dose Levetiracetam)","type":"OTHER","interventionNames":["Drug: levetiracetam"]}],"interventions":[{"name":"lacosamide","otherNames":["Vimpat"]},{"name":"levetiracetam","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adults age 18 or older\n2. Determined to have had at least two partial seizures by an epilepsy specialist, or to have had a single partial seizure with clinical and/or laboratory evidence of a high seizure recurrence risk\n3. Monotherapy on levetiracetam less than or equal to 1500 mg/day for at least two weeks\n4. Breakthrough seizure while on stable dose (\\>5 days) of levetiracetam monotherapy regimen, not due to provocative factors (e.g. hypoglycemia, head trauma, missed medications)\n\nExclusion Criteria:\n\n1. Clinical suspicion of nonepileptic psychogenic seizures or idiopathic generalized epilepsy\n2. Pregnant, child-bearing age not using contraception, or breast feeding\n3. Medical contraindication to adding lacosamide\n4. History of antiepileptic drug (AED) polytherapy\n5. Presence of a vagus nerve stimulator\n6. Creatinine clearance of less than 50 mL/min\n7. Blood pressure instability: pulse \\<50 or \\>100, systolic blood pressure (SBP) \\<50 or \\>180, clinically significant electrocardiogram (EKG) abnormality\n8. History of significant drug rash or anaphylactic reaction with antiepileptic drug\n9. Patients with progressive lesions (e.g. brain tumors)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Six Month Seizure Freedom","description":"Seizure freedom is defined as having no seizures and was evaluated in the 6 month period after receiving the drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null},{"groupId":"OG001","value":"41.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seizure-Free Days","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118.11","spread":"68.59"},{"groupId":"OG001","value":"114.0","spread":"65.06"}]}]}]},{"type":"SECONDARY","title":"Time to First Seizure After Therapeutic Dose is Reached","description":"Time in days until the first seizure after the therapeutic dose is reached occurs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.0","spread":null},{"groupId":"OG001","value":"116.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Retention Rate","description":"Retention rate is defined as the percentage of participants who remained on the study drug after study completion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAE)","description":"An Adverse Event (AE) is defined as any untoward medical occurrence (side effect) in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event that occurs after receiving the drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Irritability/depression","Fatigue","Dizziness","Memory/cognitive difficulties/confusion","Erectile dysfunction"]}}}